These concerns stemmed from fears of fluctuating BCR::ABL1 levels or disease relapse, and, for those who discontinued TKI for pregnancy, worries about adverse fetal effects and/or the fetus inheriting CML. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.